Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. New Zealand
  4. New Zealand Stock Exchange
  5. TruScreen Group Limited
  6. News
  7. Summary
    TRU   NZTRUE0001S7

TRUSCREEN GROUP LIMITED

(TRU)
  Report
End-of-day quote. End-of-day quote New Zealand Stock Exchange - 07/23
0.065 NZD   -1.52%
07/08TRUSCREEN : Director Nominations Closing Date
PU
07/01TRUSCREEN : First Sales Made in Eastern Europe
PU
06/30TRUSCREEN : to Ship Cervical Cancer Screening Devices to Serbia in July
MT
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TruScreen : Opening of Public Offer and Publication of Research Report

11/25/2020 | 04:29pm EDT
As previously announced to the market on 9 November 2020, cervical cancer screening technology company, TruScreen Group Limited (NZX: TRU)(TruScreen or the Company) intends to undertake a capital raising initiative, by way of a public offer, to raise up to NZD$2 million ('Offer') in conjunction with TruScreen's application for the dual listing of its shares on the Australian Securities Exchange (ASX).The Offer opens today the 26 November 2020 and applications can be made through the online application portal at https://www.truscreenshareoffer.co.nz/. A copy of the registered Product Disclosure Statement in support of the Offer is available on the online application portal.

The Offer will close on 18 December 2020 ('Closing Date').
An application has been made to the ASX for TruScreen to be admitted to the Official List of ASX as an ASX Foreign Exempt Listing and for quotation of the new shares to be offered in Australia on the ASX.

If TruScreen is admitted to the official list of ASX, then those Australian based investors in the Offer will have their Shares quoted on the ASX.

The Offer is conditional upon the ASX approving the admission of TruScreen to the Official List of the ASX as an ASX Foreign Exempt Listing and for the quotation of the new shares issued to Australian investors on the ASX on or before that Closing Date (as that date may be varied from time to time). In the event that this condition is not satisfied, then the Offer will not proceed, and all application moneys received by the Company will be refunded to investors in full and without deduction within 5 business days.

An issuer sponsored Research Report on TruScreen prepared by leading biotech analyst Stuart Roberts of Pitt Street Research Pty Limited was published by Pitt Street Research on 23 November 2020. A copy of the report is available on the Company's website at https://bit.ly/3nQG6qt

Disclaimer

TruScreen Limited published this content on 26 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2020 21:28:00 UTC


© Publicnow 2020
All news about TRUSCREEN GROUP LIMITED
07/08TRUSCREEN : Director Nominations Closing Date
PU
07/01TRUSCREEN : First Sales Made in Eastern Europe
PU
06/30TRUSCREEN : to Ship Cervical Cancer Screening Devices to Serbia in July
MT
06/01TRUSCREEN : FY21 Preliminary Results
PU
03/24TRUSCREEN : Research Confirms TruSreeen Suitability in COVID-19 Environment
PU
03/23TRUSCREEN : Cervical Cancer Screening Device Suitable for COVID-19 Environment
MT
03/01TRUSCREEN : Board Appointment
PU
03/01TruScreen Group Limited Announces Board Changes
CI
02/25TRUSCREEN : Executive Leadership Change
PU
02/25TruScreen Group Limited Announces Executive Changes
CI
More news
Financials
Sales 2021 1,97 M 1,38 M 1,38 M
Net income 2021 -3,49 M -2,43 M -2,43 M
Net cash 2021 5,26 M 3,67 M 3,67 M
P/E ratio 2021 -9,18x
Yield 2021 -
Capitalization 23,6 M 16,4 M 16,5 M
EV / Sales 2020 6,02x
EV / Sales 2021 15,5x
Nbr of Employees -
Free-Float 69,8%
Chart TRUSCREEN GROUP LIMITED
Duration : Period :
TruScreen Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Last Close Price 0,07 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Juliet Hull Chief Executive Officer & Director
Guy Robertson Chief Financial Officer & Secretary
Peng Ho Non-Executive Chairman
Edmond Capcelea Chief Technology Officer
Nicole Melia Manager-Administration & Marketing
Sector and Competitors